Sangamo Therapeutics (SGMOQ) Research & Development (2010 - 2025)

Sangamo Therapeutics' Research & Development history runs 16 years deep, the most recent figure standing at $31.4 million for Q4 2025.

• On a quarterly basis, Research & Development rose 32.79% year-over-year to $31.4 million in Q4 2025; TTM through Dec 2025 was $112.7 million, a 1.03% increase from a year earlier, with the FY2025 full-year figure at $112.7 million, up 1.03% from the prior year.
• Research & Development climbed to $31.4 million in Q4 2025 per SGMOQ's latest filing, from $28.1 million in the prior quarter.
• Across five years, Research & Development topped out at $66.2 million in Q4 2022 and bottomed at $23.7 million in Q4 2024.
• The 5-year median for Research & Development is $54.1 million (2021), against an average of $46.9 million.
• Across the five-year window, Research & Development surged 44.71% in 2021 and tumbled 61.58% in 2024, its largest moves.
• Year by year, Research & Development stood at $51.8 million in 2021, then gained by 27.76% to $66.2 million in 2022, then decreased by 23.38% to $50.7 million in 2023, then sank by 53.31% to $23.7 million in 2024, then jumped by 32.79% to $31.4 million in 2025.
• Per Business Quant, the three latest SGMOQ Research & Development figures stand at $31.4 million (Q4 2025), $28.1 million (Q3 2025), and $27.1 million (Q2 2025).